Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Bioorg Chem. 2021 Apr;109:104703. doi: 10.1016/j.bioorg.2021.104703. Epub 2021 Feb 8.
A series of new quinazolinone-dihydropyrano[3,2-b]pyran derivatives 10A-L were synthesized by simple chemical reactions and were investigated for inhibitory activities against α-glucosidase and α-amylase. New synthesized compounds showed high α-glucosidase inhibition effects in comparison to the standard drug acarbose and were inactive against α-amylase. Among them, the most potent compound was compound 10L (IC value = 40.1 ± 0.6 µM) with inhibitory activity around 18.75-fold more than acarboase (IC value = 750.0 ± 12.5 µM). This compound was a competitive inhibitor into α-glucosidase. Our obtained experimental results were confirmed by docking studies. Furthermore, the cytotoxicity of the most potent compounds 10L, 10G, and 10N against normal fibroblast cells and in silico druglikeness, ADME, and toxicity prediction of these compounds were also evaluated.
一系列新型的喹唑啉酮-二氢吡喃并[3,2-b]吡喃衍生物 10A-L 通过简单的化学反应合成,并对其抑制α-葡萄糖苷酶和α-淀粉酶的活性进行了研究。与标准药物阿卡波糖相比,新合成的化合物表现出较高的α-葡萄糖苷酶抑制作用,对α-淀粉酶没有活性。其中,最有效的化合物是化合物 10L(IC 值为 40.1±0.6µM),其抑制活性比阿卡波糖(IC 值为 750.0±12.5µM)高约 18.75 倍。该化合物是α-葡萄糖苷酶的竞争性抑制剂。我们的实验结果得到了对接研究的证实。此外,还评估了最有效的化合物 10L、10G 和 10N 对正常成纤维细胞的细胞毒性,以及这些化合物的类药性、ADME 和毒性预测。